New strategy tested for lung cancer that outsmarts first treatment
Disease control
Recruiting now
This study is for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation) and has started growing again after their first targeted treatment. Researchers want to see if giving a higher dose of the drug furmonertinib, or combining a stand…
Phase: PHASE2 • Sponsor: Jialei Wang • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC